An “immune-privileged” site was created there, allowing the tumors to gain the ability of adaptive immune resistance, probably because the PD-1: PD-L1 interaction could functionally suppress the capacity of tumor infiltrating lymphocytes (TILs) to produce effector cytokines and subsequent promote virus-induced malignant transformation (50). The gene discussed is CD274; the disease is neoplasm.